Two companies aim for 2nd-gen COVID vaccines
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
Rentschler Biopharma to produce 100m doses of CureVac vaccine
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NVs RNA-based COVID-19 vaccine candidate CVnCoV.
Italian Enthera Pharma raise 35m in Series A extension
Enthera Pharmaceuticals extends its 28m Series A financing from last July to a total of 35m as Roche Venture Fund joins the companys investor syndicate.
German antibodies in demand in USA
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Omnix Medical bags 10.8m from EIC Accerator Fund
Israels Omnix Medical has been granted 10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
Germany orders antibody therapies from USA
Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
Servier and MiNA Therapeutics sign 220m deal
French Servier SA and the UKs MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
LSP leads 21m round into Neurent Medical
Irish life sciences company Neurent Medical has closed a 21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
Janssen presents one-shot COVID-19 vaccine data
J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
German researchers find reason for remdesivir’s inefficiency
German Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.